- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02643511
Hemiablative Focal Brachytherapy Pilot Study
Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer
Whole gland LDR brachytherapy has been a well established modality of treating low risk prostate cancer. Treatment in a focal manner has the advantages of reduced toxicity to surrounding organs.
AIM: To determine the utility of focal LDR brachytherapy in form of hemiablative treatment for localized prostate cancer demonstrating the feasibility of the delivery of the prescription dose to the half of the prostate in terms of meeting standard dosimetric parameters while respecting same or lower tolerance doses of adjacent normal organs.
To determine acute and late rectal, urinary and sexual toxicity after this procedure.
To assess the change from baseline in QOL indicators at specific time intervals using validated international questionnaires [International Prostate Symptom Score ( IPSS), International Index of Erectile Function ( IIEF ), Expanded Prostate Cancer Index (EPIC)] after this treatment.
To evaluate the local tumour control in terms of biopsy outcomes after focal brachytherapy 36 months after the treatment.
To compare target coverage and relative doses to the rectum and the urethra for the same patient performing a hemigland treatment planning vs Whole gland treatment planning.
STUDY DESIGN: Multi-institution prospective trial to determine whether hemiablative treatment with LDR for prostate cancer is dosimetrically safe and feasible.This study will record data for 20 patients with ipsilateral with low and low tier intermediate risk disease.The study will record quality of life parameters in particular in terms of urinary, rectal and sexual function side effects.
INTERVENTION:
- Baseline Transperineal Template guided mapping prostate biopsy with >20 cores (not required if already performed)
- Multiparametric MRI within the 3 months prior to registration and at 18 & 36 months.
- Hemigland prostate region will be targeted with the prescription dose and receive 144 Gy of Iodine125 (I125).
- The quality of life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life
- Postimplant CT Planning day 30 after the implant for quality assurance.
MEASUREMENT OF ENDPOINTS :
Dosimetric parameters record, Toxicity and QOL evaluation forms, PSA follow up and biopsies at 36 months to assess local control.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ana Fernandez, MD
- Phone Number: +61291131306
- Email: ana.fernandezots@sesiahs.health.nsw.gov.au
Study Contact Backup
- Name: Joseph Bucci, MD
- Phone Number: +61291133831
- Email: joseph.bucci@sesiahs.health.nsw.gov.au
Study Locations
-
-
New South Wales
-
Kogarah, Sydney, New South Wales, Australia, 2217
- Recruiting
- St George Hospital Cancer Care Centre
-
Contact:
- Ana Fernandez, MD
- Phone Number: +61291131306
- Email: ana.fernandezots@sesiahs.health.nsw.gov.au
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Patients must have histologically proven adenocarcinoma of the prostate.
2. Patients must have low or low-tier intermediate prostate cancer
Low risk prostate cancer patients must have:
- Clinical stage ≤ T2a,
- Gleason score =6 and iPSA ≤ 10 ng/ml
- < 25% cores positive, < 50 % cancer in each core involved
Low tier Intermediate risk patients may have:
- Clinical stageT2a
- Gleason score ≤ 3+4=7
- PSA ≤ 10 ng/ml
< 25% cores positive, < 50 % cancer in each core
3. Patients must be fit for general anesthetic. 4. Patients must have unilateral disease on biopsy 5. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2.
6. Men ≥ 65 years of age with a life expectancy estimated to be >10 years. 7. Patients must have no contraindications to interstitial prostate brachytherapy.
8. Patients on anticoagulant therapy must be able to stop therapy safely for at least 7 days.
9. Patients must not have any contraindications to MRI 10. IPSS <=16
Exclusion Criteria:
- Does not meet staging criteria for low risk or low tier intermediate risk prostate cancer
- Bilateral prostatic disease
- Prior hormonal therapy
- Prior Transurethral resection or middle lobe resection
- Recent IPSS>
- Unfit for general anesthetic
- MRI contraindicated
- Unable to cease anticoagulant therapy
- Life expectancy < 10 years
- IPSS>16
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prostate biopsy,Hemiablative focal Brachytherapy
This is a non-randomized, Phase II study examining the efficacy in terms of postimplant dosimetry (primary endpoint) as well as the secondary endpoints of QOL changes, toxicity, local control with post-treatment biopsy outcomes and comparison with historical whole-gland cohorts in men with early stage low volume prostate cancer treated with hemiablative focal brachytherapy
|
A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions.
Hemiablative Focal brachytherapy will be performed .
The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125).
A postimplant dosimetry will be performed 30 days after procedure.
The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life.
The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment.
A second transperineal biopsy will be performed 36 months after the implant.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Optimal dosimetric parameters to target and organs at risk in day 30 postimplant dosimetry
Time Frame: 1month to 3 years
|
Acceptable dosimetric parameters in Day 30 postimplant dosimetry as per brachytherapy guidelines
|
1month to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rates of acute and late toxicity assessed by CTCAE v4.0
Time Frame: 6months to 10years
|
Treatment related toxicities will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
|
6months to 10years
|
Change from baseline in QOL in Genitourinary aspect
Time Frame: 6 months to 10 years
|
This will be assessed using the IPSS questionnaire
|
6 months to 10 years
|
Change from baseline in QOL in the sexual aspect
Time Frame: 6 months to 10 years
|
This will be assessed using the IIEF questionnaire
|
6 months to 10 years
|
Change from baseline in QOL in the gastrointestinal aspect
Time Frame: 6 months to 10 years
|
This will be assessed using the EPIC questionnaire
|
6 months to 10 years
|
Local control as Negative prostate biopsy 36 months after the treatment
Time Frame: 3 years after treatment
|
3 years after treatment
|
|
Dosimetric parameters comparison between hemigland treatment vs Whole gland historical cohort
Time Frame: 6 months to 10 years
|
6 months to 10 years
|
|
Grade of genitourinary and gastrointestinal toxicity assessed by CTCAE v4.0 comparison between hemigland treatment vs Whole gland historical cohort
Time Frame: 6 months to 10 years
|
6 months to 10 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STGAF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
Clinical Trials on Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
-
I.M. Sechenov First Moscow State Medical UniversityCompletedProstate Cancer | Prostate AdenocarcinomaRussian Federation
-
University College London HospitalsAdvanced Medical Diagnostics s.a.Unknown